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AbstrACt
background Spartalizumab is a humanized IgG4κ 
monoclonal antibody that binds programmed death-1 
(PD-1) and blocks its interaction with PD- L1 and PD- L2. 
This phase 1/2 study was designed to assess the safety, 
pharmacokinetics, and preliminary efficacy of spartalizumab 
in patients with advanced or metastatic solid tumors.
Methods In the phase 1 part of the study, 58 patients 
received spartalizumab, intravenously, at doses of 1, 3, 
or 10 mg/kg, administered every 2 weeks (Q2W), or 3 or 
5 mg/kg every 4 weeks (Q4W).
results Patients had a wide range of tumor types, most 
commonly sarcoma (28%) and metastatic renal cell 
carcinoma (10%); other tumor types were reported in ≤3 
patients each. Most patients (93%) had received prior 
antineoplastic therapy (median three prior lines) and two- 
thirds of the population had tumor biopsies negative for 
PD- L1 expression at baseline. The maximum tolerated dose 
was not reached. The recommended phase 2 doses were 
selected as 400 mg Q4W or 300 mg Q3W. No dose- limiting 
toxicities were observed, and adverse events included 
those typical of other PD-1 antibodies. The most common 
treatment- related adverse events of any grade were fatigue 
(22%), diarrhea (17%), pruritus (14%), hypothyroidism 
(10%), and nausea (10%). Partial responses occurred in two 
patients (response rate 3.4%); one with atypical carcinoid 
tumor of the lung and one with anal cancer. Paired tumor 
biopsies from patients taken at baseline and on treatment 
suggested an on- treatment increase in CD8+ lymphocyte 
infiltration in patients with clinical benefit.
Conclusions Spartalizumab was well tolerated at all 
doses tested in patients with previously treated advanced 
solid tumors. On- treatment immune activation was 
seen in tumor biopsies; however, limited clinical activity 
was reported in this heavily pretreated, heterogeneous 
population. The phase 2 part of this study is ongoing in 
select tumor types.
trial registration number NCT02404441.
bACkground
Programmed death-1 (PD-1) is an inhibitory 
receptor expressed on a variety of immune 
cells, including activated T cells, regulatory 
T cells, and B cells.1 2 Interaction between 
PD-1 and its ligands, PD- L1 or PD- L2, leads to 
downregulation of effector T cell responses 
and mediates immune tolerance.3 4 PD-1 
and PD- L1 are commonly upregulated on 
tumor- infiltrating lymphocytes and a wide 
variety of tumor cells, respectively.1 5 6 Mono-
clonal antibodies (mAbs) targeting PD-1 can 
restore effector T cell function and antitumor 
activity7 and have shown clinical benefit in 
patients with advanced cancers.8 9 Spartali-
zumab (PDR001) is a humanized IgG4κ mAb 
that binds PD-1 with subnanomolar activity 
in vitro and blocks interaction with PD- L1/
PD- L2 in cell- based assays. Spartalizumab has 
also demonstrated pharmacodynamic (PD) 
activity and a favorable toxicology profile in 
preclinical studies, outlined in the Results 
section; notable differences from other PD-1 
antibodies have not been observed. This first- 
in- human phase 1/2 study was designed to 
investigate the safety, pharmacokinetics (PK), 
and efficacy of spartalizumab in patients with 
advanced or metastatic solid tumors. Here, 




In vitro binding of spartalizumab to PD-1 was 
assessed using surface plasmon resonance 
(Biacore). PD-1 immunoglobulin was cova-
lently bound as ligand to a CM-5 chip, and 
spartalizumab was passed over in serial dilu-
tions at a rate of 50 µL/min.
Spartalizumab was tested for its ability 
to block the binding of PD- L1 and PD- L2 
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to PD-1 in a competitive flow cytometry binding assay. 
Murine 300.19 cells expressing PD-1 were incubated with 
solutions that contained a constant concentration of 
PE- labeled PD- L1- Fc or PD- L2- Fc and serial dilutions of 
spartalizumab at 4°C for 4 hours. Bound labeled PD- L1- Fc 
or PD- L2- Fc were then quantified using fluorescence- 
activated cell sorting (FACS), and half maximal inhibitory 
concentration (IC50) values were derived from best- fit 
competition curves generated with Prism GraphPad 
software.
Clinical study design
This was a phase 1/2, multicenter, open- label study 
(NCT02404441), designed and sponsored by Novartis 
Pharmaceuticals Corporation. The data cut- off date was 
October 5, 2018.
study objectives
The primary objective for the phase 1 part of the study 
was to estimate the recommended phase 2 dose (RP2D) 
and/or maximum tolerated dose (MTD) for spartali-
zumab. Secondary objectives included characterization of 
the safety and tolerability, and the PK profile of spartali-
zumab, and evaluation of the preliminary efficacy of spar-
talizumab. Exploratory objectives included assessment of 
potential predictive biomarkers for efficacy.
Patient selection
Eligible patients had locally advanced and/or metastatic 
solid tumors that had progressed on standard therapy, 
were intolerant to therapy, or for whom no standard 
therapy exists. Patients were aged ≥18 years and had 
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of ≤2. Patients were required to have 
measurable disease or non- measurable disease using 
Response Evaluation Criteria In Solid Tumors (RECIST) 
v1.1, to have tumor(s) amenable to biopsy, and to give 
consent to tumor biopsy at baseline and during therapy 
with study drug. Key exclusion criteria included symp-
tomatic central nervous system (CNS) metastases or CNS 
metastases requiring local therapy, impaired cardiac 
function or clinically significant cardiac disease, a history 
of severe hypersensitivity reactions to mAbs or drug- 
induced pneumonitis, and active, known, or suspected 
autoimmune disease. Immunosuppressive medication 
was not permitted, and patients were not eligible if they 
had received prior PD-1– or PD- L1–directed therapy at 
any time, or systemic anticancer therapy, radiotherapy, or 
major surgery within 2 weeks prior to the start of treat-
ment. Concomitant chemotherapy and/or radiotherapy 
were not permitted.
treatment plan
The starting dose of spartalizumab was 1 mg/kg, adminis-
tered intravenously, every 2 weeks (Q2W), with an option 
to amend to schedules of every 3 weeks (Q3W) or every 
4 weeks (Q4W). Treatment was administered until unac-
ceptable toxicity, progressive disease as per immune- 
related response criteria (irRC),10 or patient/physician 
decision. Dose escalation decisions were based on all 
available safety, PK, and PD data, guided by an adaptive 
Bayesian logistic regression model (BLRM) following 
the escalation with overdose control (EWOC) principle. 
Treatment was discontinued if more than two consecutive 
doses were missed due to toxicity; delays of up to 7 days to 
allow recovery from adverse events (AEs) were permitted.
safety assessments
Dose- limiting toxicities (DLTs, defined in the study 
protocol, online supplementary file 1) were assessed 
during the first 28 days of treatment. Regular safety assess-
ments were performed, based on physical examination, 
ECOG performance status, laboratory parameters, and 
cardiac assessments. AEs, defined by the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events V.4.03, were assessed at every visit.
response assessments
Efficacy was evaluated by local investigator’s assessment 
using RECIST v1.1 and irRC. Tumor assessments were 
performed at baseline and subsequent assessments were 
performed at 8 weeks, then every 8 weeks up to 40 weeks, 
then every 12 weeks until progression of disease per irRC, 
withdrawal of consent, or lost to follow- up.
Pk assessments
Samples were collected for PK profiling on Days 1, 2, 3, 
4, 8, 11, and 15 of Cycles 1 and 3, and Day 1 of Cycles 2, 
4, 5, and 6, and at end of treatment. Serum concentra-
tions were determined with liquid chromatography mass 
spectrometry.
Pd analyses
An archival tumor sample and a newly obtained pretreat-
ment tumor biopsy were collected at screening. There 
was no limit on the age of the archival tumor samples. 
An additional tumor biopsy was obtained during treat-
ment, either in Cycle 2 or Cycle 3. PD- L1 levels in tumor 
cells were assessed centrally by immunohistochemistry 
(IHC) using a diagnostic developed for non- small cell 
lung cancer (NSCLC; Dako PD- L1 IHC 22C3 pharmaDx) 
and CD8+ levels were assessed by IHC, expressed as CD8+ 
staining as a percentage of the total sample area.
results
Preclinical activity of spartalizumab
In vitro binding studies have shown that the mean disso-
ciation constant (KD) values for spartalizumab binding 
to human and cynomolgus PD-1 were 0.83 and 0.93 nM, 
respectively; no binding was detected with mouse PD-1 
(online supplementary table S1). In a cell- based assay, 
spartalizumab showed IC50 values of 0.9 and 1.3 nM for 
inhibiting the binding of PD-1 to PD- L1 and PD- L2, respec-
tively (average of three experiments; online supplemen-
tary table S1). PD activity has also been demonstrated in 
vitro; spartalizumab induced a concentration- dependent 
increase in interferon gamma (IFNγ) release in a mixed 
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Median age, years (range) 47 (26–77) 61 (25–82) 54 (37–82) 52 (25–59) 56 (23–73) 54.5 (23–82)
Sex (male), n (%) 7 (43.8) 8 (53.3) 7 (63.6) 4 (66.7) 6 (60.0) 32 (55.2)
Race, n (%)
  Caucasian 10 (62.5) 14 (93.3) 8 (72.7) 4 (66.7) 8 (80.0) 44 (75.9)
  Black 2 (12.5) 0 0 0 0 2 (3.4)
  Asian 3 (18.8) 1 (6.7) 2 (18.2) 2 (33.3) 1 (10.0) 9 (15.5)
  Unknown 1 (6.3) 0 0 0 0 1 (1.7)
  Other 0 0 1 (9.1) 0 1 (10.0) 2 (3.4)
ECOG PS, n (%)
  0 8 (50.0) 2 (13.3) 5 (45.5) 3 (50.0) 6 (60.0) 24 (41.4)
  1 8 (50.0) 13 (86.7) 6 (54.5) 2 (33.3) 4 (40.0) 33 (56.9)
  2 0 0 0 1 (16.7) 0 1 (1.7)
Primary tumor type, n (%)
  Anal cancer 0 0 2 (18.2) 0 0 2 (3.4)
  ATC 0 1 (6.7) 0 0 0 1 (1.17)
  Breast cancer 0 1 (6.7) 1 (9.1) 0 1 (10.0) 3 (5.2)
   TNBC 0 1 (6.7) 0 0 0 1 (6.7)
  Carcinoid 0 1 (6.7) 0 0 0 1 (1.7)
  Cholangiocarcinoma 0 1 (6.7) 1 (9.1) 0 0 2 (3.4)
  Esophageal cancer 0 0 1 (9.1) 1 (16.7) 0 2 (3.4)
  H&N cancer 1 (6.3) 1 (6.7) 0 0 1 (10.0) 3 (5.2)
  HCC 2 (12.5) 0 0 0 0 2 (3.4)
  Melanoma, cutaneous 0 0 1 (9.1) 0 0 1 (1.7)
  Merkel cell carcinoma 0 0 1 (9.1) 0 1 (10.0) 2 (3.4)
  Mesothelioma 0 1 (6.7) 0 0 0 1 (6.7)
  mRCC 2 (12.5) 1 (6.7) 1 (9.1) 1 (16.7) 1 (10.0) 6 (10.3)
  Neuroendocrine carcinoma 2 (12.5) 0 0 0 0 2 (3.4)
  NSCLC, adenocarcinoma 0 1 (6.7) 0 0 0 1 (1.7)
  Ovarian cancer 1 (6.3) 0 0 1 (16.7) 0 2 (3.4)
  Prostate cancer 1 (6.3) 0 0 0 0 1 (1.7)
  Sarcoma 4 (25.0) 4 (26.7) 2 (18.2) 2 (33.3) 4 (40.0) 16 (27.6)
   Liposarcoma 2 (12.5) 1 (6.7) 0 0 0 3 (5.2)
  SCLC 0 1 (6.7) 1 (9.1) 0 0 2 (3.4)
  Solid tumor 0 0 0 0 1 (10.0) 1 (1.7)
  Squamous cell carcinoma of skin 0 0 0 0 1 (10.0) 1 (1.7)
  Testicular cancer 1 (6.3) 0 0 0 0 1 (1.7)
  Urothelial carcinoma 0 1 (6.7) 0 1 (6.7) 0 2 (3.4)
  Other 2 (12.5) 1 (6.7) 0 0 0 3 (5.2)
Prior treatment regimens, n (%)
  0 0 1 (6.7) 1 (9.1) 0 2 (20.0) 4 (6.9)
  1 4 (25.0) 2 (13.3) 1 (9.1) 0 0 7 (12.1)
  2 2 (12.5) 7 (46.7) 2 (18.2) 1 (16.7) 2 (20.0) 14 (24.1)
  ≥3 10 (62.5) 5 (33.3) 7 (63.6) 5 (83.3) 6 (60.0) 33 (56.9)
Continued



















Prior radiotherapy, n (%)
  Yes 7 (43.8) 8 (53.3) 8 (72.7) 2 (33.3) 6 (60.0) 31 (53.4)
  No 9 (56.3) 7 (46.7) 3 (27.3) 4 (66.7) 4 (40.0) 27 (46.6)
PD- L1+ cells, n (%)
  <1% 11 (68.8) 9 (60.0) 7 (63.6) 5 (83.3) 7 (70.0) 39 (67.2)
  1–<5% 1 (6.3) 3 (20.0) 0 0 0 4 (6.9)
  5–<50% 2 (12.5) 2 (13.3) 2 (18.2) 0 2 (20.0) 8 (13.8)
  ≥50% 1 (6.3) 1 (6.7) 1 (9.1) 0 1 (10.0) 4 (6.9)
  Missing 1 (6.3) 0 1 (9.1) 1 (16.7) 0 3 (5.2)
ATC, anaplastic thyroid cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; H&N, 
head and neck cancer; mRCC, metastatic renal cell carcinoma; NSCLC, non- small cell lung cancer; PD- L1, programed death ligand 1; Q2W, 
once every 2 weeks; Q4W, once every 4 weeks; SCLC, small cell lung cancer; TNBC, triple- negative breast cancer.
Table 1 Continued
lymphocyte reaction assay (eightfold to 13- fold increase 
relative to isotype control antibody), and enhanced inter-
leukin-2 (IL-2) production in a Staphylococcal entero-
toxin B ex vivo functional assay (twofold to threefold 
increase).
Preclinical toxicity
In preclinical toxicology studies, repeated administra-
tion of spartalizumab was well tolerated in cynomolgus 
monkeys following once weekly intravenous administra-
tion at doses up to 100 mg/kg, for up to 14 weeks. Expo-
sure in monkeys exceeded that seen in patients at 400 mg 
intravenous Q4W. Microscopic changes comprised 
macrophage infiltrates in the spleen, perivascular mono-
nuclear cell infiltrates and/or fibrosis at the intravenous 
injection site, and vascular/perivascular mononuclear 
cell infiltrates in multiple tissues, which were generally 
of minimal to mild severity. These findings are consistent 
with the known biology associated with PD-1 blockade, 
which leads to the disinhibition of endogenous immune 
responses.
Clinical patient population, treatment, and disposition
Patient demographics and baseline characteristics are 
shown in table 1. The median age was 54.5 years (range 
23–82) and 98% of patients had an ECOG performance 
status of 0 or 1. Patients had a wide range of primary tumor 
types, most commonly sarcoma (16 patients, 28%) and 
metastatic renal cell carcinoma (6 patients, 10%); other 
tumor types were reported in three or fewer patients each. 
The majority of patients had received prior antineoplastic 
therapy (93%), including neoadjuvant and/or adjuvant 
therapies, with a median of three prior regimens (range 
0–11). Five patients had received prior immunotherapy, 
none of which were checkpoint inhibitors. At the data cut- 
off date (October 5, 2018), 58 patients had been treated 
in the phase 1 part of the study. Patients received spartali-
zumab, intravenously, at doses of 1, 3, or 10 mg/kg, Q2W 
(n=42), or 3 or 5 mg/kg, Q4W (n=16). All patients discon-
tinued from the study due to progressive disease (81%), 
patient or physician decision (10%), death (7%; due to 
study indication (n=2), progressive disease (n=1), and 
respiratory failure (n=1)), or AEs (2%; grade 3 dyspnea, 
not suspected to be related to treatment).
dlts, Pk, and rP2d
No patient experienced a DLT, assessed in the first 28 
days of treatment. PK parameters are shown in table 2 
and concentration–time profiles by dose/regimen are 
shown in figure 1. Exposure was approximately dose- 
proportional from 1 to 10 mg/kg Q2W and from 3 to 
5 mg/kg Q4W based on Cycle 1 PK parameters. The 
observed mean half- life for spartalizumab ranged from 
11 to 41 days, but this must be interpreted with caution 
due to the short observation window. The targeted Cycle 
3 AUC0–336h levels of over 1000 day*µg/mL were reached 
with doses of 3 mg/kg Q2W and 5 mg/kg Q4W, compa-
rable to levels achieved with other PD-1 inhibitors. The 
PK data were used to build a population PK model which 
examined the effect of bodyweight on spartalizumab PK. 
Based on the safety profiles observed at 3 mg/kg Q2W 
and 5 mg/kg Q4W and the population PK modeling, the 
corresponding flat dose of 400 mg Q4W was selected as 
the RP2D.11 An every 3 week dosing regimen with the 
equivalent weekly dose, 300 mg Q3W, was selected as an 
alternative regimen.11 These two doses achieved similar 
exposure; alternate dosing regimens may permit flexi-
bility for combination with other therapies.
safety and tolerability
All patients experienced at least one AE and 36 patients 
(62%) experienced grade 3/4 AEs, regardless of relation-
ship to study treatment, as detailed in online supplemen-
tary table S2. No fatal AEs were observed. AEs suspected 
to be related to study treatment were experienced by 
34 patients (59%; table 3); the most frequent (≥10% of 
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Mean values (SD) provided, except for Tmax, which is median (range).
AUCtau, area under the curve, 0–672 hours for Q4W or 0–336 hours for Q2W; Cmax, maximum serum concentration; Q2W, once every 2 weeks; 
Q4W, once every 4 weeks; T1/2, half life; Tmax, time at Cmax.
patients) were fatigue (13 patients; 22%), diarrhea (10 
patients; 17%), pruritus (8 patients; 14%), hypothy-
roidism, and nausea (each 6 patients; 10%). Grade 3/4 
AEs suspected to be related to study treatment were 
reported in two patients (3.4%); autoimmune colitis 
(biopsy confirmed) in one patient and decreased weight, 
hyperglycemia, and hypocalcemia in one patient. Both 
patients continued treatment; the patient with autoim-
mune colitis had an interruption to treatment. Grade 3 
autoimmune colitis was the only on- treatment AE classi-
fied as a serious AE suspected to be related to treatment; 
this patient also experienced serious grade 2 pneumonitis 
over 2 months after receiving the last dose of treatment. 
The most commonly observed AEs of special interest 
(including immune- related AEs) suspected to be related 
to treatment were diarrhea (10 patients; 17%), pruritus 
(8 patients; 14%), and hypothyroidism (6 patients; 10%; 
online supplementary table S3).
Preliminary efficacy
The median duration of exposure to treatment was 
13 weeks (range 2–110). Thirty- six per cent of patients 
received treatment for ≥20 weeks, and four patients 
received treatment for longer than 12 months (figure 2B). 
Forty- four patients out of 58 were evaluable for best 
percentage change in sum of target lesion diameters from 
baseline (figure 2A); a subset of patients was not evalu-
able due to unavailable post- baseline assessments (n=9: 
discontinued due to progressive disease, n=5; death, n=2; 
subject/guardian decision, n=1; AE not suspected to be 
related to treatment, n=1); non- measurable disease (n=4), 
or post- baseline assessment method different from base-
line assessment (n=1). Partial responses were observed 
in two patients and stable disease was experienced by 
22 patients, including one patient with undifferentiated 
liposarcoma who had stable disease persisting for over 24 
months (table 4; figure 2C).
6 Naing A, et al. J Immunother Cancer 2020;8:e000530. doi:10.1136/jitc-2020-000530
Open access 
Figure 1 Median concentration–time profiles for 
spartalizumab, by treatment group. (A) Cycle 1. (B) Cycle 3. 
Q2W, once every 2 weeks; Q4W, once every 4 weeks.




















All Gr 3/4 All Gr 3/4 All Gr 3/4 All Gr 3/4 All Gr 3/4 All Gr 3/4
Total 10 (62.5) 1 (6.3) 10 (66.7) 0 5 (45.5) 1 (9.1) 3 (50.0) 0 6 (60.0) 0 34 (58.6) 2 (3.4)
  Fatigue 5 (31.3) 0 2 (13.3) 0 2 (18.2) 0 1 (16.7) 0 3 (30.0) 0 13 (22.4) 0
  Diarrhea 4 (25.0) 0 4 (26.7) 0 1 (9.1) 0 0 0 1 (10.0) 0 10 (17.2) 0
  Pruritus 3 (18.8) 0 5 (33.3) 0 0 0 0 0 0 0 8 (13.8) 0
  Hypothyroidism 2 (12.5) 0 1 (6.7) 0 1 (9.1) 0 0 0 2 (20.0) 0 6 (10.3) 0
  Nausea 3 (18.8) 0 1 (6.7) 0 1 (9.1) 0 0 0 1 (10.0) 0 6 (10.3) 0
  Decreased appetite 2 (12.5) 0 0 0 1 (9.1) 0 0 0 1 (10.0) 0 4 (6.9) 0
  Anemia 2 (12.5) 0 1 (6.7) 0 0 0 0 0 0 0 3 (5.2) 0
  Constipation 3 (18.8) 0 0 0 0 0 0 0 0 0 3 (5.2) 0
  Dizziness 3 (18.8) 0 0 0 0 0 0 0 0 0 3 (5.2) 0
  Dry mouth 1 (6.3) 0 1 (6.7) 0 0 0 0 0 1 (10.0) 0 3 (5.2) 0
  Maculopapular rash 1 (6.3) 0 2 (13.3) 0 0 0 0 0 0 0 3 (5.2) 0
  Vomiting 2 (12.5) 0 0 0 1 (9.1) 0 0 0 0 0 3 (5.2) 0
Gr, grade; Q2W, once every 2 weeks; Q4W, once every 4 weeks.
Of the two responding patients, one patient (10 mg/
kg Q2W) had a diagnosis of anal cancer, for whom the 
duration of response was approximately 1.8 months at the 
last assessment, and the best percentage decrease from 
baseline in sum of target lesion diameters was 31%. The 
response was ongoing when this patient discontinued 
from the study. This patient experienced serious auto-
immune colitis and pneumonitis and discontinued due 
to patient decision; the patient subsequently died due 
to disease progression, over a year after discontinuation 
from the study. The other responding patient (3 mg/kg 
Q2W) had a diagnosis of atypical carcinoid tumor of the 
lung (neuroendocrine). The duration of response was 
approximately 8.5 months, after which the patient devel-
oped progressive disease. The best percentage decrease 
from baseline in sum of target lesion diameters was 77%, 
and responses were seen in multiple lesions, in the liver, 
pleura, and lymph nodes (figure 3A,B).
biomarker analyses
Tumor tissue samples obtained at baseline and on treat-
ment were analyzed by IHC for PD- L1 expression (Dako 
PD- L1 IHC 22C3 pharmaDx) and CD8+ T cell infiltration 
(positive IHC staining as a percentage of total sample area; 
online supplementary table S4). The majority of patients 
(n=39; 67%) were negative for baseline PD- L1 expression 
(<1%), 12 patients (21%) had baseline PD- L1 expression 
≥5%, and four patients (7%) had baseline PD- L1 expres-
sion ≥50%. Approximately 50% of patients had both base-
line and on- treatment (Cycle 2 or 3) biopsy samples. A 
correlation was seen between an on- treatment increase 
in biomarker evidence of inflammation and a decrease 
in sum of target lesion diameters, both for PD- L1 expres-
sion (n=28; Spearman coefficient=−0.49) and CD8+ T cell 
infiltration (n=32; Spearman coefficient=−0.42; online 
supplementary figure S1).
For the patient with anal cancer who experienced a 
partial response, baseline PD- L1 expression was 10% 
with an increase to 50% observed at the Cycle 2 Day 
1 (C2D1) biopsy; CD8+ T cell infiltration was 0.5% in 
the tumor sample obtained at baseline and 2.7% in the 
sample obtained on C2D1. For the patient with atypical 
carcinoid tumor of the lung who experienced a partial 
response, baseline PD- L1 expression was 0%; however, 
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Figure 2 Percentage change from baseline in target 
lesions and duration of exposure to spartalizumab. (A) 
Best percentage change from baseline in target lesions, 
by PD- L1 expression at baseline. Best overall response 
is shown for each patient according to RECIST v1.1. (B) 
Duration of exposure to spartalizumab, by treatment group. 
Best overall response and response at last assessment 
are shown. (C) Percentage change from baseline in target 
lesions over time, by PD- L1 expression at baseline. Best 
overall response is shown for each patient according to 
RECIST v1.1. * Unavailable; # Non- measurable disease. ATC, 
anaplastic thyroid cancer; BOR, best overall response; EMC, 
extraskeletal myxoid chondrosarcoma; H&N, head and neck; 
HCC, hepatocellular carcinoma; mRCC, metastatic renal cell 
carcinoma; non- CR/non- PD, non- complete response/non- 
progressive disease; NSCLC, non- small cell lung cancer; PD, 
progressive disease; PD- L1, programmed death ligand 1; 
PR, partial response; Q2W, once every 2 weeks; Q4W, once 
every 4 weeks; RECIST, Response Evaluation Criteria In Solid 
Tumors; SCC, squamous cell carcinoma; SCLC, small cell 
lung cancer; SD, stable disease; TNBC, triple- negative breast 
cancer; UNK, unknown.
Table 4 Best overall response (investigator assessed 
according to RECIST v1.1)
All patients
N=58
Best overall response, n (%)
  Complete response 0
  Partial response 2 (3.4)
  Stable disease 22 (37.9)
  Progressive disease 25 (43.1)
  Unknown 9 (15.5)
Overall response rate, % (90% CI) 3.4 (0.6 to 10.5)
Disease control rate, % (90% CI) 41.4 (30.4 to 53.0)
The 90% CI was calculated using the exact (Clopper- Pearson) 
interval.
Overall response rate=complete plus partial responses; disease 
control rate=complete and partial responses plus stable disease.
Stable disease includes patients with best overall response of non- 
complete response/non- progressive disease.
RECIST, Response Evaluation Criteria In Solid Tumors.
Figure 3 Tumor response assessments and 
immunohistochemistry of CD8+ lymphocyte infiltration in 
patient with atypical carcinoid tumor of the lung with a partial 
response to treatment. (A) Reduction in overall tumor burden 
(upper) and individual lesions (lower). (B) CT scans of the 
liver: (i) liver metastasis pretreatment; (ii) pseudo- progression 
at first restaging; (iii) response at second restaging. (c) High 
levels of CD8 detected by immunohistochemistry during 
Cycle 2. PD, progressive disease; PR, partial response; Q2W, 
every 2 weeks; Q4W, every 4 weeks; SD, stable disease.
CD8+ lymphocyte infiltration was observed in a fresh 
tissue biopsy obtained from this patient at baseline 
(CD8=5.6%), with an increase to 37.6% observed at the 
C2D1 biopsy (figure 3C).
For the patient with liposarcoma who experienced 
stable disease for >2 years, both PD- L1 expression (base-
line PD- L1=0%) and CD8 staining were low (baseline 
CD8=0.2%; C2D1 CD8=0.2%). A second patient with 
liposarcoma (well- differentiated) received treatment 
for >1 year (stable disease >9 months) and on- treatment 
increases were seen for both PD- L1 expression (baseline 
PD- L1=0%; C3D1 PD- L1=80%) and CD8 staining (base-
line CD8=0.2%; C3D1 CD8=18.8%). A number of other 
patients with stable disease were found to have on- treat-
ment increases in one or both markers, including a patient 
with triple- negative breast cancer (TNBC) and stable 
disease lasting ~8 months (baseline PD- L1=0%; C2D1 
PD- L1=10%; baseline CD8=1.6%; C2D1 CD8=2.5%) and 
a patient with ovarian cancer and stable disease lasting ~2 
months (baseline PD- L1=0%; C2D1 PD- L1=5%; baseline 
CD8=0.7%; C2D1 CD8=2.8%).
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disCussion
Treatment with spartalizumab was generally well toler-
ated in this phase 1 study. The incidence of grade 3/4 
AEs suspected to be related to treatment was low, and 
toxicities were consistent with what has been observed 
with other anti–PD-1 antibodies.12 13 The PK parameters 
of spartalizumab were characterized from 1 to 10 mg/kg 
Q2W and from 3 to 5 mg/kg Q4W. The data generated 
were used to build a population PK model which exam-
ined the effect of bodyweight on spartalizumab PK. At 
3 mg/kg Q2W and 5 mg/kg Q4W, PK exposure exceeded 
1000 day*µg/mL, which is comparable with marketed 
PD-1 inhibitors.14 Based on the population PK model, a 
flat dose of 400 mg Q4W was selected as the RP2D, and 
the predicted steady- state concentration of spartalizumab 
at this dose was sufficient for PD-1 blockade.11 15 This dose 
was therefore selected as the RP2D, with an alternative 
dosing schedule of 300 mg Q3W expected to achieve 
similar exposure. The availability of two dosing schedules 
should facilitate combination with other antineoplastic 
regimens.
The clinical activity observed in this phase 1 study was 
limited; however, this may be explained in part by the 
fact that the patient population was heavily pretreated 
and relatively depleted of patients with tumor types now 
known to be responsive to anti–PD-1 antibodies, such 
as NSCLC and melanoma8 16–18; only one patient with 
NSCLC and one with melanoma were included in this 
phase 1 study. Furthermore, less than a third of patients 
in the phase 1 part had tumor biopsies positive for PD- L1 
expression, which is associated with response to anti–
PD-1 therapies.19 Response rates of 7%–28% have been 
observed in the preliminary reports from the phase 2 part 
of this study, in patients with NSCLC, melanoma, and 
anaplastic thyroid cancer (ATC).20 21
Partial responses were observed in two patients in 
the dose escalation part of the study reported here; 
one response in a patient with anal cancer and one 
durable response in a patient with atypical carcinoid. 
Both patients had evidence of an on- treatment immune 
response, and the patient with anal cancer had PD- L1+ 
tumor cells at baseline. A number of other patients had 
stable disease, and although this alone is not evidence 
of clinical activity, paired tumor biopsies from some of 
these patients showed an increase in CD8+ lymphocyte 
infiltration on- treatment, consistent with the mechanism 
of action for spartalizumab. Evidence of immune acti-
vation in tumors, including an increase in intratumoral 
CD8+ lymphocytes and plasma IFNγ, has also been seen in 
patients with melanoma receiving a combination of spar-
talizumab with BRAF and MEK inhibitors.22 It may be that 
patients with a PD response to spartalizumab treatment 
harbor additional resistance mechanisms that prevent a 
tumor response. If so, these patients may benefit from 
combination treatment with spartalizumab and other 
therapies.
The phase 2 part of this study is ongoing and is investi-
gating the safety and efficacy of spartalizumab in patients 
with ATC, TNBC, NSCLC, and melanoma; exploration of 
potential predictive biomarkers is also ongoing.20 21 Spar-
talizumab is also being investigated in combination with 
other immunotherapies and targeted therapies.
ConClusions
Spartalizumab was well tolerated in patients with advanced 
solid tumors. The RP2D was selected as 400 mg Q4W or 
300 mg Q3W. Limited clinical activity was seen in this 
heavily pretreated patient population, which enrolled 
relatively few patients with tumor types known to be 
responsive to PD-1 blockade or with positive tumor PD- L1 
expression. Treatment with spartalizumab resulted in 
immune activation in tumors, consistent with the mecha-
nism of action for spartalizumab.
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